# 125I Seed Brachytherapy Combined With Immunotherapy for Primary, Recurrent, or Metastatic Malignant Tumors

> **NCT07277777** · PHASE2 · NOT_YET_RECRUITING · sponsor: **Li Min** · enrollment: 90 (estimated)

## Conditions studied

- Malignant Tumors

## Interventions

- **DRUG:** Immune Checkpoint Inhibitors
- **OTHER:** 125I Seed Implantation
- **DRUG:** Immune Checkpoint Inhibitors

## Key facts

- **NCT ID:** NCT07277777
- **Lead sponsor:** Li Min
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-01
- **Primary completion:** 2027-01-01
- **Final completion:** 2028-01-01
- **Target enrollment:** 90 (ESTIMATED)
- **Last updated:** 2026-01-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07277777

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07277777, "125I Seed Brachytherapy Combined With Immunotherapy for Primary, Recurrent, or Metastatic Malignant Tumors". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT07277777. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*